Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline

Megan E. Daly, Navneet Singh, Nofisat Ismaila, Mara B. Antonoff, Douglas A. Arenberg, Jeffrey Bradley, Elizabeth David, Frank Detterbeck, Martin Früh, Matthew A. Gubens, Amy C. Moore, Sukhmani K. Padda, Jyoti D. Patel, Tanyanika Phillips, Angel Qin, Clifford Robinson, Charles B. Simone

Research output: Contribution to journalArticlepeer-review

110 Scopus citations


PURPOSETo provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC).METHODSAn Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RESULTSThe literature search identified 127 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONSEvidence-based recommendations were developed to address evaluation and staging workup of patients with suspected stage III NSCLC, surgical management, neoadjuvant and adjuvant approaches, and management of patients with unresectable stage III NSCLC.Additional information is available at

Original languageEnglish
Pages (from-to)1356-1384
Number of pages29
JournalJournal of Clinical Oncology
Issue number12
StatePublished - Apr 20 2022


Dive into the research topics of 'Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline'. Together they form a unique fingerprint.

Cite this